Argenta Discovery and Porsolt have entered into an alliance to provide CNS and pain drug discovery services. The collaboration allows the two companies to undertake fully integrated CNS and pain-focused drug discovery programs for their clients, from hit identification to development candidate nomination. Dr. Christopher Ashton, chief executive officer of Argenta said, “Argenta has undertaken many successful medicinal chemistry-driven CNS and pain contract drug discovery research projec...